The Gary Null Show - 09.19.22

Videos : New Rule: Let the Population Collapse | Real Time with Bill Maher (HBO) – 8:29 The De-Population Bomb – hoover institution (0:43 – 8:15) THE GREAT AWAKENING: PLANDEMIC 3 PRELAUNCH PARTY – (21:00 – 30:20) Gary Null Speaking Out at the NYS Assembly Hearing  (25:00)   Meta-analysis finds less fatigue with CoQ10 supplementationNational Yang Ming Chiao Tung University (Taiwan), September 16 2022. The results of a systematic review and meta-analysis of clinical trials, published in Frontiers in Pharmacology, support an anti-fatigue effect among individuals who supplemented with coenzyme Q10. “Coenzyme Q10 (CoQ10) is a popular nutritional supplement and a lipid-soluble antioxidant that is endogenously produced by the human body,” authors I-Chen Tsai of National Yang Ming Chiao Tung University and associates observed. “CoQ10 supplementation has been successfully applied for reducing fatigue in patients with various conditions, including chronic fatigue and fibromyalgia, as well as in healthy subjects.” For their analysis, Tsai colleagues identified 13 randomized, controlled trials that compared fatigue scores of participants who received CoQ10 or a placebo. The trials included a total of 1,126 participants. Analysis of the 13 trials showed a consistent significant effect for CoQ10 in reducing fatigue. When trials that included healthy participants were analyzed separately from trials that included patients with fatigue-associated diseases, both supplemented populations showed decreases in fatigue, however the effects were significant among the unhealthy participants, who may have more severe CoQ10 depletion. Higher CoQ10 doses and longer duration of supplementation were correlated with increased fatigue reduction. The anti-fatigue effect of CoQ10 is unsurprising, given its role in energy production. Chronic fatigue syndrome patients have lower plasma levels of CoQ10 in comparison with healthy subjects. While the body makes some CoQ10, the authors remarked that studies have provided evidence that supplementing with CoQ10 does not affect the body’s synthesis of the coenzyme. Researchers identify a potential new approach with a dietary supplement to treat HER2 positive breast cancerMayo Clinic, September 9, 2022 Researchers at Mayo Clinic have identified an important new pathway by which HER2 positive breast cancers grow and have discovered that a dietary supplement called cyclocreatine may block the growth of HER2 positive breast cancer. Their findings were published in Cell Metabolism. “The HER2 receptor tyrosine kinase, which functions as an ‘on’ or ‘off’ switch in cellular functions, is a key driver of breast cancer, and is overexpressed in about a quarter of all breast cancers,” says Taro Hitosugi, Ph.D., a pharmacologist at Mayo Clinic and corresponding author of the paper. Dr. Hitosugi and his colleagues decided to explore ways to resolve an unmet clinical need. Their strategy was to develop a treatment to target tumor mitochondrial energy metabolism, which is the process cancer cells use to manipulate energy during cell metabolism in order to grow. Dr. Hitosugi and his colleagues discovered that cyclocreatine, a dietary supplement used in sports drinks, effectively targets mitochondrial creatine kinase 1 enzyme and reduces cancer growth without toxicity. This finding was confirmed in mice models where a patient-derived, trastuzumab-resistant HER2 positive tumors were administered to the mice. “Mitochondrial creatine kinase 1 may be a new drug target for the treatment of HER2 positive breast cancer,” says Matthew Goetz, M.D., director of the Mayo Clinic Breast Cancer research program. “Future clinical trials will be necessary to determine the effectiveness of this drug for HER2 positive breast cancer resistant to standard therapies.” Excessive smartphone screen time linked to earlier puberty onsetGazi University (Turkey), September 16, 2022 Exposure to blue light, via regular use of tablets and smartphones, ma